Abstract Library

#4597 FIT-NETs: Assessing the effects of an exercise programme on the physical and emotional well-being of patients with advanced G1-2 NETs of GEP or unknown origin

Introduction: Physical activity programs in solid tumours have shown to improve symptom control and even survival, but their impact on NENs remains unexplored. Advanced disease, systemic therapy, and hormonal secretion in these tumours often lead to muscle wasting and sarcopenia.

Conference:

Presenting Author: Anton-Pascual B

Authors: Anton-Pascual B, Rodriguez-Gomez J, de Cima A, Herrero-Llorente A, Modrego A,

Keywords: FIT-NET, physical exercise program, Quadriceps, MEP & MIP, QoL,

#4529 Long-term quality of life after pancreatic surgery for neuroendocrine tumours of the pancreas: Outcome of 100 patients evaluated with new EORTC questionnaires

Introduction: Patients with Pancreatic Neuroendocrine Tumours (PanNETs) often have a good prognosis with long overall survival.

Conference:

Presenting Author: Milanetto A

Authors: Milanetto A, Armellin C, Veronese E, Lorenzoni G, Pasquali C,

Keywords: net, pancreatic, quality of life,

#4222 Quali-NET: A prospective study on patient-reported quality of life in neuroendocrine neoplasms

Introduction: Neuroendocrine neoplasms of the lung (LNEN) or gastro-enteropancreatic tract (GEPNEN) are typically slow-growing, leading to longer overall survival, and resembling chronic illnesses. Therefore, focus on quality of life (QoL) is crucial. While brief studies have been done, comprehensive, long-term studies are needed.

Conference:

Presenting Author: Islam O

Authors: Islam O, Depauw L, van der Massen I, Simoens M, Galdermans D,

Keywords: GEP-NEN, LNEN, Quality of life, Longitudinal data,

#4131 Peptide receptor radionuclide therapy (PRRT) in patients with neuroendocrine neoplasms: A prospective multi-site study evaluating quality of life and objective response

Introduction: Neuroendocrine neoplasms (NENs) are associated with poor health-related quality of life (HRQOL) due to tumor and hormonal related symptoms and treatment-related toxicity. Peptide receptor radionuclide therapy (PRRT) delivers targeted therapy for tumor and hormonal control.

Conference:

Presenting Author: Cehic G

Authors: Cehic G, Kong G, Corsini N, Chan D, Pavlakis N,

Keywords: PRRT, NENs, HRQOL,

#4095 CAPTEM and PRRT to improve overall response for pancreatic NETs (pNETs) – The CORONET trial

Introduction: Patients with advanced pNETs have limited treatment options. The NETTER-2 and OCLURANDOM trials have established peptide receptor radionuclide therapy (PRRT) as a standard treatment in pNETs; CAPTEM chemotherapy is an active regimen in NENs. The CONTROL NETs trial has shown promising response rate and progression-free survival with PRRT+CAPTEM, warranting further investigation.

Conference:

Presenting Author:

Authors: Chan D, Doherty M, Singh S, Michael M, Kong G,

Keywords: PRRT, CAPTEM, Randomized Trial, Phase III,